PuSH - Publication Server of Helmholtz Zentrum München: Baseline fibroblast growth factor 23 is associated with long-term mortality in ST-elevation myocardial infarction-results from the augsburg myocardial infarction registry.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Schmitz, T.* ; Wein, B.* ; Heier, M. ; Peters, A. ; Meisinger, C.* ; Linseisen, J.*

Baseline fibroblast growth factor 23 is associated with long-term mortality in ST-elevation myocardial infarction-results from the augsburg myocardial infarction registry.

Front. Cardiovasc. Med. 10:1173281 (2023)

Publ. Version/Full Text

DOI

PMC

	Open Access Gold

Abstract
Metrics
Extra information

BACKGROUND: The aim of this study was to investigate the association between inflammatory plasma protein concentrations and long-term mortality in patients with ST-elevation myocardial infarction (STEMI). METHODS: For 343 STEMI patients recorded between 2009 and 2013 by the population-based Myocardial Infarction Registry Augsburg, 92 inflammatory plasma proteins were measured at the index event using the OLINK inflammation panel. In multivariable-adjusted Cox regression models, the association between each plasma protein and all-cause long-term mortality was investigated. Median follow-up time was 7.6 (IQR: 2.4) years. For plasma protein that showed a strong association with long-term mortality, a 5-year survival ROC analysis was performed. RESULTS: One plasma protein, namely Fibroblast Growth Factor 23 (FGF-23), was particularly well associated with long-term mortality in the multivariable-adjusted Cox model with an FDR-adjusted p-value of <0.001 and a Hazard Ratio (HR) of 1.57 [95% CI: 1.29-1.91]. In the 5-years ROC analysis, an AUC of 0.6903 [95% CI: 0.594-0.781] was estimated for FGF-23. All other plasma protein didńt show strong associations, each marker with FDR-adjusted p-values >0.05 in the multivariable-adjusted Cox models. CONCLUSIONS: FGF-23 is independently associated with long-term mortality after STEMI and might play an important role in the response to myocardial injury. The results suggest FGF-23 to be a useful marker in the long-term treatment of STEMI patients and a potential target for drug development.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Fgf-23 ; Stemi ; Inflammatory Plasma Protein ; Long-term Mortality ; Myocardial Infarction; Cardiovascular Events; Heart-failure; Ami-registry; Fgf23; Disease; Risk; Fgf-23; Monica/kora; Population; Biomarkers

ISSN (print) / ISBN 2297-055X

e-ISSN 2297-055X

Journal Frontiers in Cardiovascular Medicine

Quellenangaben Volume: 10, Article Number: 1173281

Publisher Frontiers

Publishing Place Lausanne

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Institute of Epidemiology II (EPI2)

Grants Medical Faculty of the University of Augsburg
BMBF (German Ministry of Education and Research)
DZHK (German Centre for Cardiovascular Research)
German Federal Ministry of Health
State of Bavaria
Helmholtz Zentrum Muenchen, German Research Center for Environmental Health - German Federal Ministry of Education, Science, Research and Technology